Clinical Trials Logo

Clinical Trial Summary

This is an open label, Phase I/IIa trial of immunotherapy with CreaVax-PC as treatment in men with hormone-Refractory Metastatic Prostate Cancer.


Clinical Trial Description

CreaVax-PC consisted of antigen (PSA, PAP and KLH) primed dendritic cell is an investigational product designed to activate a man's immune response, so they can detect prostate cancer cells and initiate an immune response against prostate cancer antigens.

If patients decide to participate and are eligible, they will be enrolled in the study and will receive active product (CreaVax-PC). In detail, patients will receive CreaVax-PC injection at intervals of 3 weeks, maximum 6 times during 21 weeks. PSA increase rate is a primary evaluation variables and tumor suppression effect is secondary evaluation variables. We also evaluate time to progression, overall survival and immune response. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01171729
Study type Interventional
Source Samsung Medical Center
Contact
Status Completed
Phase Phase 1/Phase 2
Start date July 2006
Completion date May 2010

See also
  Status Clinical Trial Phase
Withdrawn NCT05191017 - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Phase 1/Phase 2
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Completed NCT01086956 - Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy N/A
Completed NCT00643617 - CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry N/A
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02687308 - Open Anterograde Radical Prostatectomy Compared to Open Retrograde Technique N/A
Completed NCT01284608 - Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT) N/A
Completed NCT04421781 - Salvage HIFU for Local Recurrence in the Prostatic Bed After Prostatectomy and External Beam Radiation Therapy : Preliminary Results
Recruiting NCT05740956 - A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT03173924 - 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer Phase 2
Not yet recruiting NCT05851521 - To Evaluate LUTS and Complications Between Indwelling Catheter and Temporary Prostatic Stent in Patients Undergoing Minimally Invasive Procedures for the Treatment of Localized Prostate Cancer or Benign Prostatic Hyperplasia (HERMES) N/A
Completed NCT01998685 - Prothrombotic Factors and Anaesthesia in Prostate Cancer N/A
Completed NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study Phase 2
Not yet recruiting NCT06439784 - Contribution of the VERITON-CT Camera in Prostate Bone Radiostereotaxy N/A
Terminated NCT03606889 - Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia N/A
Completed NCT03481816 - Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines Phase 1
Recruiting NCT05623878 - 68Ga-labeled NY108 PET Imaging in Patients Early Phase 1
Not yet recruiting NCT05184790 - LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
Completed NCT02564120 - North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)
Active, not recruiting NCT01787630 - To Evaluate the Technique and Effects of Separating the Prostate and Rectum With Hyaluronic Acid During Radiotherapy Phase 2/Phase 3